Physician profile
Amanda Spence
NPI 1437624087
$7,788.45
in general payments reported to CMS, 2019-2025
42 companies · $3,057 in 2025
The $3,057 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.50 · 2023: $2,022 · 2024: $2,696 · 2025: $3,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,755 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,755.33 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,020.02 | 2021-2025 | |
| Novo Nordisk INC | $474.64 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $435.93 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $414.94 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Neurocrine Biosciences, INC. | $391.47 | 2023-2025 | Ingrezza |
| Pfizer INC. | $388.75 | 2023-2025 | |
| Amgen INC. | $289.29 | 2023-2025 | Evenity, Prolia, Prolia |
| Axsome Therapeutics, INC. | $260.40 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $241.67 | 2023-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $235.54 | 2023-2025 | Bevespi Aerosphere, Fasenra, Airsupra |
| Exact Sciences Corporation | $214.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $208.44 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.84 | 2023-2025 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.47 | 2023-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.20 | 2023-2025 | Caplyta |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $134.87 | 2023-2024 | Azstarys |
| Paratek Pharmaceuticals, INC. | $130.62 | 2023-2024 | Nuzyra |
| Amneal Pharmaceuticals LLC | $128.63 | 2025 | Unithroid |
| Astellas Pharma US INC | $127.66 | 2023-2024 | Veozah |
| Indivior INC. | $106.55 | 2024-2025 | Sublocade |
| Novartis Pharmaceuticals Corporation | $96.09 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $95.48 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.76 | 2023-2025 | Glassia, Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $89.33 | 2025 | |
| Sumitomo Pharma America, INC. | $73.36 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $67.35 | 2023-2025 | Livalo, Seglentis, Zoryve |
| Azurity Pharmaceuticals, INC. | $67.13 | 2023-2025 | Alvesco, Edarbyclor |
| Teva Pharmaceuticals USA, INC. | $61.89 | 2024-2025 | Austedo Xr, Austedo Xr |
| Qol Medical, LLC | $58.98 | 2023-2024 | Sucraid, Sucraid |
| Impel Pharmaceuticals INC. | $49.58 | 2023 | Trudhesa |
| Corcept Therapeutics | $44.17 | 2023 | Korlym |
| Kyowa Kirin, INC. | $41.88 | 2023 | Crysvita |
| Verona Pharma, INC. | $39.49 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $34.28 | 2024-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Madrigal Pharmaceuticals | $34.05 | 2025 | Rezdiffra |
| Lundbeck LLC | $32.82 | 2025 | Vyepti |
| Actelion Pharmaceuticals US, INC. | $30.14 | 2024 | Opsumit, Uptravi |
| Dermavant Sciences, INC. | $29.14 | 2024 | Vtama |
| Otsuka America Pharmaceutical, INC. | $25.63 | 2025 | Rexulti |
| Seqirus USA INC | $23.70 | 2025 | Fluad, Flucelvax |
| Vanda Pharmaceuticals INC. | $20.89 | 2025 | Fanapt |
| Insulet Corporation | $18.05 | 2024 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.